Account Login
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Blueprint Medicines Corp (NQ: BPMC)
84.06 USD  +2.33 (+2.85%)
Official Closing Price  /  Updated: 5:58 PM EDT, Aug 16, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 449,700
Open 82.79
Bid (Size) 72.00 (5)
Ask (Size) 91.82 (1)
Prev. Close 81.73
Today's Range 82.11 - 84.93
52wk Range 44.58 - 102.98
Shares Outstanding 43,837,337
Dividend Yield N/A
Performance
YTD
+64.24%
+64.24%
1 Month
-12.74%
-12.74%
3 Month
+3.39%
+3.39%
6 Month
+10.47%
+10.47%
1 Year
+18.85%
+18.85%
Top News
More News
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
-- FDA grants priority review and sets PDUFA date for February 14, 2020 -- Read More
from PR Newswire
Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Andy Boral, M.D., Ph.D.,... Read More
from PR Newswire
More News
Read More
Blueprint Medicines Reports Second Quarter 2019 Financial Results
from PR Newswire
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
from PR Newswire
Noteworthy Friday Option Activity: MIDD, BPMC, CVS
category Stocks
from Market News Video
Blueprint Medicines Becomes Oversold (BPMC)
category Stocks
from Market News Video
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
from PR Newswire
UPDATE 3-Deciphera shares skyrocket as cancer drug improves progression-free survival
category companyNews
from Reuters: Company News
UPDATE 2-Deciphera shares skyrocket as cancer drug improves progression-free survival
category companyNews
from Reuters: Company News
Analysts Predict 11% Upside For The Holdings of FNY
category ETFs
from ETF Channel
This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.